HARTFORD – Today, Senate President Pro Tempore Martin Looney (D-New Haven) testified before the General Assembly’s Public Health Committee in favor of two bills, Senate Bill 180, An Act Concerning Adverse Determination and Utilization Reviews, and SB 182, An Act Prohibiting Certain Health Carriers from Requiring Step Therapy for Prescription Drugs Used to Treat a Mental or Behavioral Health Condition or a Chronic, Disabling or Life-Threatening Condition.
Senator Looney testified that SB 180 “would provide a number of innovative protections for patients” and “would benefit all parties involved and make our healthcare system more effective.”
Senator also spoke in favor of SB 182 stating that “while there may be legitimate uses of step therapy, too often it is implemented in a manner that interferes with patient care and leads to insurers preventing physicians from providing the best care for patients.” He elaborated that “SB 182 would ensure that the physician is able to provide the best treatment for patients who have disabling conditions as well as cancer and behavioral health conditions. It would improve the lives of many of our citizens.”
The full testimony is available here.
|
|
